Jyong Biotech Ltd., a Taiwanese biotechnology company focused on plant-derived therapeutics, is emphasizing its strategy of forming global licensing partnerships to address unmet medical needs in urology, particularly in the treatment of Benign Prostatic Hyperplasia (BPH). Having made strides as the first Taiwanese firm to advance an oral botanical drug candidate to U.S. FDA Phase III trials, the company is exploring collaborations to enhance its global network. With a rising global BPH patient population projected to grow significantly by 2035, and existing treatments often leading to high discontinuation rates due to side effects, Jyong Biotech aims to provide safer, long-term options through its investigational drug, Botreso®.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.globenewswire.com/news-release/2026/07/23/3332361/0/en/jyong-biotech-highlights-multi-billion-dollar-global-bph-market-opportunity-and-reaffirms-strategic-focus-on-global-licensing-partnerships.html
